Zhang Jingjia, Li Gang, Zhang Ge, Kang Wei, Duan Simeng, Wang Tong, Li Jin, Huangfu Zhiru, Yang Qiwen, Xu Yingchun, Jia Wei, Sun Hongli
Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Medical Experimental Center, General Hospital of Ningxia Medical University, Yinchuan, China.
Front Microbiol. 2021 Sep 16;12:710526. doi: 10.3389/fmicb.2021.710526. eCollection 2021.
Ceftazidime-avibactam is a novel synthetic beta-lactam + beta-lactamase inhibitor combination. We evaluated the performance of the gradient diffusion strip method and the disk diffusion method for the determination of ceftazidime-avibactam against and Antimicrobial susceptibility testing of 302 clinical and isolates from two centers were conducted by broth microdilution (BMD), gradient diffusion strip method, and disk diffusion method for ceftazidime-avibactam. Using BMD as a gold standard, essential agreement (EA), categorical agreement (CA), major error (ME), and very major error (VME) were determined according to CLSI guidelines. CA and EA rate > 90%, ME rate < 3%, and VME rate < 1.5% were considered as acceptable criteria. Polymerase chain reaction and Sanger sequencing were performed to determine the carbapenem resistance genes of all 302 isolates. A total of 302 strains were enrolled, among which 182 strains were from center 1 and 120 strains were from center 2. A percentage of 18.21% (55/302) of the enrolled isolates were resistant to ceftazidime-avibactam. The CA rates of the gradient diffusion strip method for and were 100% and 98.65% (73/74), respectively, and the EA rates were 97.37% (222/228) and 98.65% (73/74), respectively. The CA rates of the disk diffusion method for and were 100% and 95.95% (71/74), respectively. No VMEs were found by using the gradient diffusion strip method, while the ME rate was 0.40% (1/247). No MEs were found by using the disk diffusion method, but the VME rate was 5.45% (3/55). Therefore, all the parameters of the gradient diffusion strip method were in line with acceptable criteria. For 31 , 33 , 7 , and 2 positive isolates, both CA and EA rates were 100%; no MEs or VMEs were detected by either method. For 15 carbapenemase-non-producing resistant isolates, the CA and EA rates of the gradient diffusion strips method were 100%. Whereas the CA rate of the disk diffusion method was 80.00% (12/15), the VME rate was 20.00% (3/15). The gradient diffusion strip method can meet the needs of clinical microbiological laboratories for testing the susceptibility of ceftazidime-avibactam drugs. However, the VME rate > 1.5% (5.45%) by the disk diffusion method. By comparison, the performance of the gradient diffusion strip method was better than that of the disk diffusion method.
头孢他啶-阿维巴坦是一种新型合成的β-内酰胺类+β-内酰胺酶抑制剂组合。我们评估了梯度扩散条法和纸片扩散法测定头孢他啶-阿维巴坦对[具体菌株1]和[具体菌株2]的性能。采用肉汤微量稀释法(BMD)、梯度扩散条法和纸片扩散法对来自两个中心的302株临床[菌株1]和[菌株2]分离株进行了头孢他啶-阿维巴坦的药敏试验。以BMD作为金标准,根据CLSI指南确定基本一致率(EA)、分类一致率(CA)、主要错误率(ME)和非常主要错误率(VME)。CA和EA率>90%,ME率<3%,VME率<1.5%被视为可接受标准。采用聚合酶链反应和桑格测序法测定所有302株分离株的碳青霉烯类耐药基因。共纳入302株菌株,其中182株来自中心1,120株来自中心2。纳入的分离株中有18.21%(55/302)对头孢他啶-阿维巴坦耐药。梯度扩散条法对[菌株1]和[菌株2]的CA率分别为100%和98.65%(73/74),EA率分别为97.37%(222/228)和98.65%(73/74)。纸片扩散法对[菌株1]和[菌株2]的CA率分别为100%和95.95%(71/74)。梯度扩散条法未发现VME,而ME率为0.40%(1/247)。纸片扩散法未发现ME,但VME率为5.45%(3/55)。因此,梯度扩散条法的所有参数均符合可接受标准。对于31株[菌株1]、33株[菌株2]、7株[菌株3]和2株[菌株4]阳性分离株,CA和EA率均为100%;两种方法均未检测到ME或VME。对于15株非产碳青霉烯酶耐药分离株,梯度扩散条法的CA和EA率均为100%。而纸片扩散法的CA率为80.00%(12/15),VME率为20.00%(3/15)。梯度扩散条法能够满足临床微生物实验室检测头孢他啶-阿维巴坦药物敏感性的需求。然而,纸片扩散法的VME率>1.5%(5.45%)。相比之下,梯度扩散条法的性能优于纸片扩散法。